Citi sees high price of Tirzepatide on Hims & Hers being ‘prohibitive’
Citi analyst Daniel Grosslight says Hims & Hers traded up 10% yesterday after Bloomberg noted the company is now offering branded ...
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
Morgan Stanley says Hims branded tirzepatide margins likely well below compounds
After Hims & Hers (HIMS) announced yesterday that the company is broadening its weight loss offering to include Lilly’s (LLY) branded ...
STAT1d
Pharmalittle: We’re reading about a ‘miracle’ HIV drug program, Lilly going after compounders, and more
The Trump administration’s cuts to a global AIDS relief program threaten to upend rollout of a groundbreaking HIV prevention ...
Investor's Business Daily on MSN11h
Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch
Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.
Eli Lilly sues Strive and Empower as FDA lifts tirzepatide shortage status
Eli Lilly is escalating its legal push to protect the exclusivity of its high-profile weight-loss and diabetes drugs, ...
Where Will Eli Lilly Be in 1 Year?
Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...